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ABSTRACT
Objective: Maraviroc is the ﬁrst approved drug in a new class of antiret-
rovirals, the CCR5 antagonists. The objective of this study was to predict
the long-term clinical impact and cost-effectiveness of maraviroc in
treatment-experienced adults with HIV/AIDS in Mexico.
Methods: The AntiRetroviral Analysis by Monte Carlo Individual Simu-
lation (ARAMIS) model was adapted to the Mexican context to predict
clinical and economic outcomes of treating with optimized background
therapy (OBT) versus testing for viral tropism status and treating with
OBT  maraviroc accordingly in treatment-experienced adults in Mexico.
Baseline characteristics and efﬁcacy were from the MOTIVATE trials’
screening cohort. Costs and population mortality data were speciﬁc to
Mexico. Results were reported from the perspective of health care payers
in 2008 Mexican pesos (converted to 2008 US$ in parentheses).
Results: Compared to treatment with OBT alone, treatment with
OBT  maraviroc contingent on tropism test result increased projected
undiscounted life expectancy and discounted quality-adjusted life expect-
ancy from 7.54 to 8.71 years and 4.42 to 4.92 quality-adjusted life years
(QALYs), respectively, at an incremental cost of $228,215 (US$21,329).
The resultant incremental cost-effectiveness ratio (ICER) was $453,978
(US$42,429) per QALY gained. The ICER was somewhat lower when
maraviroc was modeled in individuals susceptible to 2 components of
OBT ($407,329; US$38,069), while the ICER was higher in individuals
susceptible to 3 OBT components ($718,718; US$67,171).
Conclusion: In treatment-experienced individuals with HIV/AIDS in
Mexico, maraviroc may be cost-effective, particularly in individuals with
limited options for active antiretroviral therapy (ART).
Keywords: AIDS, anti-HIV agents, cost-effectiveness, economic model,
HIV, maraviroc, Mexico.
Introduction
Acquired immunodeﬁciency syndrome (AIDS) continues to be a
major health epidemic with an estimated 39.5 million people
living with human immunodeﬁciency virus (HIV) worldwide and
2.9 million people dying from AIDS in 2006 [1]. Based on data
from the Mexican National Center for the Prevention and the
Control of the HIV/AIDS, it was estimated in 2006 that 182,000
people in Mexico were living with the disease [2,3]. In 2007, the
World Health Organization (WHO) estimated HIV prevalence in
Mexico, among adults aged 15 years and older, to be 244 per
100,000 population [4]. From 1992 to 1997, only social security
beneﬁciaries had free access to antiretroviral therapies (ARTs)
and HIV care in Mexico [5]. However, by 2006, accessibility to
ART had increased to 78% of the infected Mexican population
[6].
Currently, highly active antiretroviral therapy (HAART) rep-
resents the mainstay among treatments for HIV-infected indi-
viduals, which suppress viral load, improve immune function,
and delay the progression of the disease. Since its introduction in
1996, HAART has dramatically improved survival rates for indi-
viduals with HIV infection. However, new classes of antiretrovi-
ral agents with novel mechanisms of action are now receiving
greater consideration due to side effects and poor tolerability
with existing agents and the emergence of drug-resistant viral
strains after long exposure to ART therapies, resulting in treat-
ment failure.
The newly developed drug maraviroc is the ﬁrst of a class
known as CCR5 antagonists. Maraviroc selectively and revers-
ibly binds to CCR5 receptor on CD4+ cells, preventing interac-
tion with the gp120 protein of CCR5-tropic virions and
subsequent entry. In double-blind, placebo-controlled clinical
trials, maraviroc in addition to optimized background therapy
(OBT) were compared to OBT alone in treatment-experienced
adults infected with CCR5-tropic HIV-1 [7]. Patients treated
with maraviroc achieved a substantially greater viral load reduc-
tion than did patients treated with OBT alone (-1.84 and -0.78
log10 copies/mL, respectively), with over twice the proportion of
patients achieving undetectable levels of HIV-1 (56.1% and
22.5% with <400 copies/mL at 48 weeks) [8,9].
To predict the long-term clinical and economic impact of
maraviroc as add-on therapy to OBT, we used the Anti Retroviral
Analysis by Monte Carlo Individual Simulation (ARAMIS)
model [10] to analyze the cost-effectiveness of maraviroc for the
management of individuals infected with only CCR5-tropic
HIV-1 detectable, and who have evidence of viral replication and
HIV-1 strains resistant to multiple antiretroviral agents (The
ARAMIS cost-effectiveness model is the property of Pﬁzer Inc.,
and is protected by US and international copyright laws. Unau-
thorized reproduction, modiﬁcation, republication, distribution,
or display of all, or any portion, of the ARAMIS cost-
effectiveness model is prohibited). The analysis was conducted
from the perspective of the health care payer in Mexico to a
lifetime horizon.
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Methods
Analytic Overview
The analysis was conducted using ARAMIS, a previously vali-
dated and published computer-based microsimulation model of
HIV disease progression and treatment [10]. The ARAMIS
model was designed to be applicable to countries with well-
developed systems for the care of individuals with HIV/AIDS,
and was adapted to include Mexico-speciﬁc inputs. The model
was used to extrapolate 48-week results from the MOTIVATE-1
and -2 studies and predict clinical and economic outcomes over
a lifetime, using disease progression data derived from epidemio-
logical cohort studies. Individuals screened for entry to the
MOTIVATE trials (the “MOTIVATE screening cohort”)
included adults with an HIV-1 RNA of greater than 5000
copies/mL despite at least 6 months of prior therapy with at least
one agent from three ART classes or documented resistance or
intolerance to at least one member of each class [8,9]. All indi-
viduals in the MOTIVATE screening cohort were tested for viral
tropism status, and only those in whom only CCR5 tropic virus
was detectable were eligible for entry into the trial.
The primary economic analysis was a comparison of two
treatment strategies: 1) a “contingent maraviroc” strategy in
which individuals would be treated with OBT, with or without
the addition of maraviroc according to viral tropism test results
(“OBT  maraviroc”) versus 2) an “OBT alone” strategy of
treating the entire population with OBT alone, without testing
for tropism. Hence, the economic comparison was speciﬁed
slightly differently from the design of the MOTIVATE trials, in
order to represent the ex ante policy decision on the use of
maraviroc in a treatment-experienced population, without prior
knowledge of individuals’ tropism status. The primary outcomes
of the analysis were lifetime costs, life expectancy and quality-
adjusted life years (QALYs) resulting from each treatment strat-
egy. Incremental cost effectiveness ratios (ICERs), including cost
per life year and cost per QALY gained, were calculated and
reported in 2008 Mexican pesos (with values converted to 2008
US$ reported in parentheses). The analysis was conducted using
a lifetime time horizon and a Mexican payer perspective.
The ARAMIS Model Structure and Global Parameters
The ARAMIS model has previously been described within the
context of an analysis of maraviroc conducted from a US payer
perspective [10]. The microsimulation model simulates the pro-
gression of a cohort, one individual at a time, through a set of
health states representing the natural history of HIV/AIDS from
initial infection to death. Six mutually exclusive health states are
deﬁned by CD4+ cell count categories (>500, 351–500, 201–350,
101–200, 51–100, and <50 cells/mL), and mortality is modeled as
a seventh, absorbing state (Fig. 1). In a given 1-month cycle, an
individual may remain in the same CD4+ state, progress to an
adjacent CD4+ state, enter an opportunistic infection transition
state, or die.
Disease progression is modeled as CD4+ cell decline, the
occurrence of an acute opportunistic infection, or death. CD4+
cell count is the marker of current disease state (which is tracked
at an individual patient-level using a tracker variable) [11].
Depending upon treatment status and history of opportunistic
infections, CD4+ cell count determines the subsequent risk of
opportunistic infections and HIV-related mortality that does not
occur within the acute phase of an opportunistic infection. Mor-
tality within the month immediately after a new OI (referred to
as “acute HIV mortality”) is captured separately in the model.
Data on disease progression were based on published cohort
studies [12–16]. The natural rate of decline of CD4+ cells in
untreated patients is known to be strongly related to the HIV
viral load set point (i.e., the stabilized viral load in the postacute
phase) (Table 1) [15]. As set point data were unavailable for the
study population, baseline viral load was deemed to be a reason-
able proxy for modeling the rate of decline of CD4+ cells in
patients failing treatment. The loss of CD4+ cells in HIV-infected
individuals who are untreated or failing treatment drives transi-
tion through successively lower CD4+ states, while successful
antiretroviral treatment results in reconstitution of CD4+ cells
and transitions from lower to higher CD4+ states. The CD4+ cell
count trajectory and other aspects of each individual’s simulated
lifetime clinical history are recorded within the model.
Independently of CD4+ cell count, the risk of an opportunis-
tic infection and chronic HIV mortality is modiﬁed by history of
an opportunistic infection and current exposure to antiretroviral
treatment [13,14]. In the model, causes of death include chronic
HIV disease, acute fatal opportunistic infection, and all-cause
mortality.
The probabilities of progression between health states each
cycle depend on each individual’s baseline characteristics, includ-
ing current CD4+ status, viral load set point and history of
opportunistic infections. The risk of events does not remain
ﬁxed through the model, but depends on each individual’s
accumulated history of events, particularly the occurrence of
opportunistic infections and antiretroviral treatment status. Con-
currently, individuals progress through successive lines of ART
contingent on the occurrence of virologic failure or adverse
events. With successful treatment, viral load is assumed to drop
below detectable levels (<400 copies/mL) at 48 weeks and is
described as “suppressed.” Although tests with a lower detection
limit of 50 copies/mL are now in common use, the 400 copies/mL
Figure 1 Markov state transition diagram for the ARAMIS model. OI, oppor-
tunistic infection. ↓ Denotes allowable transitions. ↑ Denotes transitions only
allowable with treatment.
Table 1 Mean monthly CD4+ cell count decline by HIV RNA stratum
[15]
HIV RNA (copies/mL)
CD4+ count
(cells/mm3)
>30,000 6.375
10,001–30,000 5.400
3,001–10,000 4.600
501–3,000 3.733
500 3.025
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criterion is used in ARAMIS because many of the clinical trials
used to calibrate the model reported only suppression rates to
<400 copies/mL [16,17]. Forty-eight weeks has become estab-
lished as a standard length of follow-up for clinical trials of ART.
In ARAMIS, when HIV is suppressed, the decline in CD4+ cell
count is arrested. If suppression is sustained, treatment speciﬁc
CD4+ count recovery is modeled with time.
Each cycle, ARAMIS updates its account of each individual’s
accumulated survival time, along with the associated costs and
quality-adjusted survival associated with his or her pathway
through themodeled health states and treatment. Speciﬁcmonthly
costs are assigned to treatment status and to each CD4+ state, the
latter representing the costs of routine health care inHIV/AIDS, as
described later. Additional cost tolls are imposedwhen individuals
experience acute opportunistic infections, which are additive to
the monthly routine care cost. Each CD4+ state and opportunistic
infection state is associated with a utility value on a 0 to 1 scale, by
which survival is quality-adjusted to allow calculation of QALYs.
Opportunistic infections are modeled as transitions that may be
encountered at each cycle. In this manner, individuals incur tran-
sition tolls (cost of treatment and quality of life decrements) when
opportunistic infections occur.
Study cohort. The distributions of the baseline characteristics of
the cohort simulated in this study were directly derived from
individual level data for the MOTIVATE screening cohort, as
previously described (mean values are shown in Table 2,
n = 3244 patients screened) [7–9]. A secondary analysis was
performed simulating the subset of individuals with only CCR5-
tropic HIV-1 detectable after tropism testing, and who were thus
eligible to enroll in MOTIVATE (the “MOTIVATE trial cohort”).
ART intervention. The treatment effects for individuals in the
OBT alone strategy and for individuals in the contingent maravi-
roc strategy who were not CCR5-tropic were derived from
pooled 48-week data from the placebo arms of the MOTIVATE
-1 and -2. The treatment effects for CCR5 positive individuals in
the maraviroc arm were derived from 48-week pooled data from
the 300 mg twice-daily maraviroc arms from the same studies
(Table 3) [8].] Within the model, CD4+ cell count increased in
each cycle that viral suppression was sustained. Consistent with
the normal pattern observed in trials of ARTs [8,18–22], a rapid
CD4+ increase was modeled during the ﬁrst two months of
effective antiretroviral therapy, and a slower rate thereafter. The
modeled rate of CD4+ cell recovery to 48 weeks was treatment-
speciﬁc and based on observed data from the MOTIVATE trials.
Beyond 48 weeks, CD4+ increases were conservatively
assumed not to differ between treatments and were estimated by
linear extrapolation from the observed trial data. Individuals
Table 2 Baseline characteristics of cohorts from the MOTIVATE trials
[8,9]
Characteristic
Screening
population
Trial population
(CCR5 monotropic)
Mean age at baseline (years) 45.3 45.6
Gender (% male) 86 87
Mean CD4+ count (cells/mL) 183.94 217.15
Viral load set point (log10 copies/mL
HIV-1 RNA)
4.72 4.76
Proportion receiving enfuvirtide with
optimized background therapy (%)
58 56
Proportion exclusively CCR5 tropic (%) 51 100
Proportion entering with history of
opportunistic infection (%)
Bacterial 7 8
Fungal 43 41
Viral 20 19
Protozoal 3 3
Other illness 30 28
Any opportunistic infection 67 63
Table 3 Efﬁcacy parameters from the MOTIVATE trials
First regimen
MVC + OBT (CCR5+) OBT alone
Mean Mean
First year virologic suppression rate (<400 copies/mL)
Pooled over both trials [8]* 56.1% 22.5%
Monthly late failure rate†
Week 48 to week 96 0.75% 1.06%
Thereafter 1.06% 1.06%
Monthly CD4+ increase when successful (cells/mL)‡
First 2 months 54.1 39.3
Months 2 to 12§ 5.4 5.3
Thereafter§ 5.6 5.6
Monthly adverse event risk (grade 3 and 4)* 1.2% 1.0%
Subsequent regimen, given failure of ﬁrst regimen
(reoptimized background therapy; rOBT) [42,43]¶
20%#
OBT + T20
80%
OBT
20%#
OBT + T20
80%
OBT
First year virologic suppression rate (<400 copies/mL) 30.4% 12% 30.4% 12%
Monthly late failure rate 1.87% 1.87% 1.87% 1.87%
Monthly CD4+ cell increase when successful (cells/mL)‡
First 2 months 33.64 16.63 33.64 16.63
Months 2 to 12 3.39 1.68 3.39 1.68
Thereafter 3.50 1.73 3.50 1.73
*Pooled 48-week data from trials A4001027 and A4001028 (MOTIVATE-1 and -2). Maraviroc efﬁcacy taken from 300 mg twice-daily maraviroc arms of trials. Pﬁzer Global Research and
Development, data on ﬁle.
†The late failure rates in fully suppressed patients are estimated by projecting the rate of viral rebound between week 16 and week 48.
‡Success is deﬁned as viral load dropping below detectable levels (<400 copies/mL) at 48 weeks.
§Estimated by linear regression on pooled (MVC and placebo arms) CD4+ count data from week 8 to 48.
¶Failure on either of the compared regimens results in a switch to an unspeciﬁed reoptimized background therapy regimen; a four-month time lag was assumed between failure and switching,
to mimic the likely delay in discovering and conﬁrming virologic failure in clinical practice.
#20% of patients were assumed to receive T20 in their subsequent OBT regimen based on unpublished information for the MOTIVATE open-label continuation phase.
MVC, maraviroc; OBT, optimized background therapy.
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who experienced virologic failure after 48 weeks were considered
“late failures.” The late failure rate was treatment-speciﬁc and
derived by linear regression from the observed failure rate from
the peak of suppression at week 8 through week 48 in the
MOTIVATE trials. As no long-term studies provide information
on sustainability of suppression beyond 10 years, all patients
modeled as suppressed at 10 years were conservatively assumed
to fail at this point in time.
After an individual failed either of the compared regimens,
they were assumed to switch to an unspeciﬁed reoptimized back-
ground therapy regimen (rOBT), based on treatment history and
the results of resistance testing. A 4-month time lag was assumed
between failure and switching, to mimic the likely delay in dis-
covering and conﬁrming virologic failure in clinical practice.
Based on unpublished data from the open-label continuation
phase of the MOTIVATE studies, it was assumed that for 20% of
these switched patients, the rOBT regimen would include enfu-
virtide. After virologic failure, the CD4+ cell count was modeled
to remain static for 12 months [23] and thereafter to decline at a
rate determined by the viral load set point [23]. For initial fail-
ures (i.e., those whose CD4+ count never reaches <400
copies/mL during their lifetime), CD4+ cell count was modeled to
remain static for 12 months after the start of the model, consis-
tent with the assumption of virologic failure to the treatment
received prior to entering the analysis. Failing patients were
assumed to remain on ART, and, consistent with evidence from
the literature [13,14], they were assumed to beneﬁt from a
reduced risk of opportunistic infection incidence conferred by
treatment in the absence of suppression.
ART-related adverse events were modeled based on pooled
rates of drug-related grade 3 and 4 adverse events from the
MOTIVATE studies, adjusted for exposure time. Monthly risks
of an adverse event for individuals receiving OBT plus maraviroc
and OBT alone were 1.2% and 1.0%, respectively.
Routine care and testing. Prophylaxis against Pneumocystis
(PCP) and Mycobacterium avium complex (MAC) was assumed
to be initiated and ended when the CD4+ cell count passed
thresholds of 200 and 50 cells per ml, respectively, and consisted
of trimethoprim-sulfamethoxazole 800 mg/160 mg (TMP-SMX)
[24]. Routine testing was assumed to include: CD4+ cell count,
HIV-1 RNA level, and, after treatment failure, genotypic resis-
tance testing, and was assumed to be performed according to US
clinical guidelines [25]. The cost of one viral tropism test was
applied to all individuals in the maraviroc treatment strategy
arm. Although the tropism test, as it was available and used in
MOTIVATE trials, is known to be imperfect, sensitivity and
speciﬁcity were set to 100% in the analysis to avoid double-
counting, because individuals with false-positive test results con-
tributed to the reported results for the OBT+ maraviroc arms of
the trials. The frequency of the remaining tests followed clinical
guidelines.
Quality of life. With the exception of the impact of adverse
events, utility values used in the model for calculating quality-
adjusted life expectancy were based on published estimates
(Table 4) [26,27]. In the absence of published utility estimates of
the impact of adverse events in HIV infection, a decrement of
0.14 was applied for one cycle, based on expert opinion, for all
patients experiencing a grade 3 or 4 adverse event. This is some-
what less than the utility decrement of 0.20 reported for gas-
trointestinal adverse events in chemotherapy [28].
Adaptation of ARAMIS to Mexico
Adaptation of ARAMIS to the Mexican setting involved use of
Mexico-speciﬁc costs, age- and gender-speciﬁc population mor-
tality data for risk of deaths due to non-HIV-related causes [29],
and a discount rate for costs and outcomes of 5% [30].
The scope of Mexico-speciﬁc costs included direct monthly
health care costs for routine HIV care (for both inpatients and
outpatients) including ART, costs of tropism testing, adverse
events associated with ART, acute and prophylactic treatment of
opportunistic infections, CD4+ cell count tests, HIV RNA tests,
treatments, and HIV- or opportunistic infection-related palliative
care preceding deaths. The daily cost of maraviroc was $181.50
(US$16.96) based on 300 mg twice daily dosing. The complete
set of cost inputs is presented in Table 5. Mexican pesos were
inﬂated [31] and converted to US$ using a published rate of $1
Mexican Peso = US$0.09346 [32].
Patterns of resource use were estimated based on a review of
patient records from nine hospitals in Mexico City belonging to
Social Security Mexican Institute (IMSS). The data collection
study gathered information from 637 patients treated for HIV/
AIDS at one of the participating hospitals during 2004 to 2005.
The study sample had an average age of 49 years (standard
deviation [SD] 9 years) and was 87% male. At the time of data
collection, patients had been infected with HIV for an average of
8.8 years (SD 2.3), with 46% of the sample being diagnosed with
AIDS and 78% having failed at least one line of therapy.
Through review of clinical records, the number of physician
visits, laboratory tests, and utilization of retroviral, non-
retroviral, and opportunistic infection-related therapies were
identiﬁed to deﬁne patterns of routine care for individuals with
HIV/AIDS. Data related to hospitalizations for HIV/AIDS-
related treatment were also collected, including length of stay
and frequency of inpatient visits, tests, surgeries, and medical
procedures. Monthly routine care costs by CD4+ cell count for
individuals with and without a history of opportunistic infection
were determined by dividing the sum of all resources used within
a year by 12 months. To determine costs associated with acute
opportunistic infection treatment, HIV/AIDS-related resources
utilized 30 days prior and 60 days after the diagnosis were
considered. Because the metropolitan area from where the par-
ticipating hospitals are located shows the highest HIV prevalence
in Mexico, it is likely that the patterns of resource utilization
observed are representative of the average treatments used in
Mexico. Drug costs were obtained from the IMSS [33], while
Table 4 Utility values by model health state
Health state Utility value Duration*
Chronic HIV by CD4+ category [26]
CD4+ >500 0.870 Present month
CD4+ 351–500 0.860 Present month
CD4+ 201–350 0.860 Present month
CD4+ 101–200 0.850 Present month
CD4+ 51–100 0.850 Present month
CD4+ <50 0.832 Present month
Acute OI [27]
Bacterial 0.561 3 months
Protozoal 0.561 3 months
Viral 0.652 3 months
Fungal 0.652 3 months
Other illness 0.561 3 months
Post-acute OI [26]
Bacterial 0.735 6 months
Protozoal 0.731 Rest of life
Viral 0.760 Rest of life
Fungal 0.743 6 months
Other illness 0.770 Rest of life
Disutility of AEs 0.140 Present month
*When more than one criterion applies, the lowest utility value is applied.
AEs, adverse events; OI, opportunistic infection.
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mean unit costs for other HIV/AIDS-related health care resources
were based on costs collected from the hospital databases of the
nine participating sites. It was assumed that patients experiencing
grade 3 or 4 adverse events due to ART incur the additional cost
of one hospital inpatient day per event; for simplicity, efforts
were not made to model individual types of adverse events.
Results
Base-Case Analysis
Applying the base-case assumptions to the MOTIVATE screening
cohort, the model predicted that the contingent maraviroc strat-
egy would lead to an increase in mean undiscounted life expect-
ancy of 14 months (15.5% increase; 8.7 vs. 7.5 years), a
10-month increase in AIDS-free survival time (38%; 35.3 vs.
25.5 months), a decrease in the proportion of individuals expe-
riencing AIDS of 2.4% (87.4% vs. 89.8%), and a decrease in the
proportion of deaths caused by HIV (87.9% vs. 90.2%) relative
to the OBT alone strategy. The contingent maraviroc strategy
produced a decrease in the incidence of all types of opportunistic
infections (19.2% vs. 20.0%) and a corresponding increase in the
mean time to the ﬁrst opportunistic infection event among inci-
dent cases (10.2 vs. 8.1 years). The average time to treatment
failure was 28.5 months for the contingent maraviroc strategy
compared to 18.7 months for the OBT alone strategy (Table 6).
Corresponding outcomes for the comparison between treating
with OBT + maraviroc versus treating with OBT alone in CCR5
monotropic individuals (i.e., based on the MOTIVATE trial
cohort) are shown in Table 6.
Figures 2 and 3 show the impact of treatment strategy on
overall survival and on the evolution of the CD4+ cell count
distribution at baseline and after 3, 5, and 7 years. The stacked
bar segments in Figure 3 represent the CD4+ categories of those
individuals in the study population who are still alive, while the
height of the bars represents the surviving proportion of the
starting population. The upper graphs show the CD4+ cell count
Table 5 Summary of cost inputs
2008 Mexican
pesos (US$)
Daily ART drug costs [33]
MVC (300 mg twice daily) 181.50 (16.96)
OBT 144.80 (13.53)
Enfuvirtide (90 mg twice daily subcutaneous
injection)
796.41 (74.43)
Routine care cost (per month)*†
No OI history
CD4+ >500 1,577 (147)
CD4+ 351–500 1,406 (131)
CD4+ 201–350 1,512 (141)
CD4+ 101–200 1,737 (162)
CD4+ 51–100 1,940 (181)
CD4+ <50 2,094 (196)
OI history 1,687 (158)
OI prophylaxis (per month) [33]
M. avium complex 223 (21)
P. carinii 9.3 (1)
Acute OIs (per episode)†
Bacterial 82,285 (7,960)
Fungal 53,928 (5,040)
Other 41,703 (3,898)
Protozoal 64,732 (6,050)
Viral 78,811 (7,366)
Last month of life costs
HIV death (assumed to be 69% of acute OI
death cost [44])
56,784 (5,307)
Acute OI death (assumed same cost as bacterial
OI episode)
82,285 (7,690)
Test costs (per test)
Tropism test 7,700 (720)
CD4+ cell count 1,249 (117)
Viral load test 2,458 (230)
Treatment-related AE‡ 4,463 (417)
*Includes inpatient and outpatient care cost during one month.
†Resource patterns and unit costs collected through review of patient records (n = 637) at
nine hospitals in Mexico.
‡Represents cost of a 1-day hospital stay.
US$ = 2008 US$.
AE, adverse event; MVC,maraviroc;OI, opportunistic infections; OBT, optimized background
therapy.
Table 6 Undiscounted clinical outcomes predicted for the base-case scenario
Clinical outcomes
MOTIVATE screening cohort MOTIVATE trial cohort (CCR5 monotropic)
Treat with
OBT alone
Test and treat with
OBTMVC
Treat with
OBT alone
Treat with
OBT+MVC
Life expectancy (years) 7.54 8.71 8.12 10.46
Proportion experiencing AIDS 89.8% 87.4% 88.0% 83.2%
AIDS-free survival (months) 25.49 35.25 31.13 50.30
Causes of death
HIV 90.2% 87.9% 89.2% 84.6%
Acute OIs 1.2% 1.2% 1.3% 1.1%
Other non-HIV/AIDS-related 8.6% 10.9% 9.5% 14.3%
Time spent on each line of therapy (months)
MVC + OBT or OBT 18.71 28.51 19.05 38.45
Subsequent reoptimized OBT 71.75 76.04 78.45 87.12
Proportion of patients experiencing ﬁrst or new OI
Bacterial 4.9% 4.7% 5.1% 4.7%
Fungal 7.1% 6.8% 7.5% 6.7%
Viral 2.2% 2.1% 2.3% 2.0%
Protozoal 3.4% 3.1% 3.6% 3.0%
Other 4.8% 4.7% 5.0% 4.9%
Mean time to OI among patients with incident OI (years)
Bacterial 9.04 10.54 9.67 12.54
Fungal 8.70 10.09 9.20 12.12
Viral 9.28 10.72 9.92 12.76
Protozoal 9.45 10.74 10.08 12.92
Other 8.50 9.76 8.98 11.45
Any 8.81 10.17 9.36 12.10
MVC, maraviroc; OI, opportunistic infection; OBT, optimized background therapy.
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distribution resulting from the use of OBT alone and
OBT  maraviroc strategies, respectively, in the MOTIVATE
screening cohort, while the lower two graphs present the CD4+
cell count distribution resulting from the use of OBT alone and
OBT + maraviroc in the MOTIVATE trial cohort, respectively.
After 3, 5, and 7 years, 22.5%, 28.1%, and 28.1% of individuals
in the MOTIVATE trial cohort treated with OBT + maraviroc
were projected to have a CD4+ cell count greater than 500, as
compared to 10.2%, 11.9%, and 11.9% of those treated with
OBT alone.
The incremental cost-effectiveness analysis results for the
MOTIVATE screening cohort are shown in the upper section of
Table 7. The estimated average discounted quality-adjusted and
unadjusted life expectancies with the OBT alone strategy were
4.4 QALYs and 5.4 years, respectively. The contingent maraviroc
strategy increased the discounted quality-adjusted and unad-
justed life expectancies by 0.5 QALYs and 0.6 years to 4.9
QALYs and 6.0 years, respectively. These beneﬁts were gained at
an incremental discounted lifetime cost of $228,215
(US$21,329), yielding ICERs of $453,978 (US$42,429) per
QALY gained and $383,904 (US$35,880) per life year gained.
The incremental cost-effectiveness results for the MOTIVATE
trial cohort are shown in lower section of Table 7. ICERs of
$443,823 (US$41,480) per QALY gained and $190,211
(US$17,777) per life year gained were predicted when comparing
a strategy of treating with OBT + maraviroc to treating with
OBT alone.
Sensitivity and Subgroup Analyses
A series of sensitivity analyses were conducted to explore the
impact on the ICERs of alternative assumptions for the values of
key input parameters. The following parameters and ranges were
tested:
1. OBT + maraviroc efﬁcacy: the mean 48-week virological
suppression for OBT + maraviroc of 56.1% was replaced
by the upper and lower bounds of the 95% conﬁdence
interval (60.8% and 51.4%);
2. OBT + maraviroc efﬁcacy: the mean 48-week virological
suppression rate (56.1%), CD4+ cell count increase (0 to 8
weeks 54.1, 8 to 48 weeks 5.4, 48 to 96 weeks 5.6), and
monthly late failure rate (-0.75% to 96 weeks then -1.06%
thereafter) for OBT + maraviroc were replaced by the upper
(suppression rate 60.8%; CD4+ increase 60.3, 6.1, 6.3; late
failure rate -0.54% then -0.72%) and lower bounds (sup-
pression rate 51.4%; CD4+ increase 47.9, 4.8, 4.9; late
Figure 2 Survival Curves (showing only ﬁrst 10 years of lifetime analysis) for
MOTIVATE screening cohort and MOTIVATE trial cohort by treatment strat-
egy.The solid curves show the predicted survival for the screening cohort.The
dotted curves represent the individuals that tested CCR5-tropic.The maraviroc
(MVC) treatment strategies are shown in grey and the OBT alone strategies are
shown in black.
Figure 3 CD4+ cell development based on
model results. The upper two charts present the
CD4+ evolution in the screening cohort; the lower
charts present the same data for the trial cohort.
The charts on the left represent treatment with
OBT alone; the charts on the right represent the
maraviroc (MVC) treatment strategies. In each
chart, the lower and darker segments of the
stacked bars represent lower CD4+ categories,
while the upper, lighter segments represent higher
CD4+ categories. The total height of the stacked
bars reﬂects the proportion of patients alive at the
indicated time points.
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failure rate -0.96% then =1.40%) of the 95% conﬁdence
intervals;
3. OBT and OBT + maraviroc efﬁcacy: the efﬁcacy parameters
for both OBT and OBT + maraviroc were changed to their
upper and then to their lower bounds simultaneously. The
parameters for OBT + maraviroc were as described above.
The mean parameters (upper, lower 95% CI) for OBT were:
suppression rate 22.5% (28.1%, 16.8%); CD4+ cell count
increase 39.3 (53.3, 25.2), 5.3 (7.8, 2.2), and 5.6 (6.3, 4.9),
respectively; and late failure rate -1.06% (-0.72%,
-1.40%);
4. OBT and OBT + maraviroc efﬁcacy: the late failure rates for
OBT and OBT + maraviroc were changed to their upper and
then to their lower bounds assuming the values described
previously;
5. Rates of CD4+ cell increase after 48 weeks for suppressed
patients: were changed from the base-case values of 5.6 cells
per month (OBT + maraviroc), 5.6 cells per month (OBT
alone), 3.5 cells per month (rOBT + T20), and 1.75 cells per
month (rOBT alone) to zero (i.e., no CD4+ increase) to test
the most conservative scenario;
6. Viral load set point: which was estimated using the
observed viral load of the MOTIVATE trial population at
baseline was changed to the lowest category (<50 copies/
mL) and to the highest category (>100,000 copies/mL)
because set point data were not available and the accuracy
of our base-case assumption is therefore not known;
7. For patients that are still suppressed, the time at which they
are assumed to fail treatment: was assumed to be 10 years
in the base-case. For sensitivity analysis, this cutoff point
was set to 5 and 100 years;
8. The time to treatment failure and failure rate for patients on
all treatments: was set to 2, 4, 6, 8, and 10 years after
treatment initiation, assuming a constant rate of failure
from 1 year for all patients using the DEALE approach (i.e.,
1/life expectancy). Failure two years after treatment initia-
tion, for example, means that everyone fails treatment
between week 48 and 96.
9. Lag time between treatment failure and switch to OBT: was
changed from its base-case assumption of 4 months to 2 and
6 months, reﬂecting a window of -/+ 50%;
10. Proportion of CCR5 monotropic patients: was changed
from its baseline value of 51% to 30% and 80% to reﬂect
the variation that may be observed in treated populations;
11. Sensitivity and speciﬁcity of the tropism test: were changed
from the base-case values of 100% and 100%, respectively,
to 85% and 94%, respectively. The base-case values of
100% were selected based on the fact that the efﬁcacy data
for patients in the OBT + maraviroc arms of the trials
already reﬂects false positives. Therefore, the results of this
sensitivity analysis in which the sensitivity and speciﬁcity
values were lowered should be considered with caution
because this approach allows for double-counting;
12. Cost of maraviroc: $181.50 per day was changed to $165
and $220 per day (US$: $16.96, $15.42, and $20.56,
respectively) reﬂecting potential variation in the drug cost
within the Mexican market;
13. Cost of OBT: $144.80 per day was increased and decreased
by 50% reﬂecting the fact that OBT is based on individual
resistance proﬁles and can vary greatly among patients;
14. Variation in utility values: was assessed by altering the
base-case values by 10% that covers generally the ranges
of utility values published by other researchers [34,35];
15. Discount rate: for costs and outcomes was set to zero to
assess the impact of discounting.
In addition to the deterministic and multiway sensitivity
analyses, a subgroup analysis was conducted. In the MOTIVATE
trials, phenotypic and genotypic resistance to protease inhibitors
(PIs), nucleoside reverse transcriptase inhibitors (NRTIs) and
non-nucleoside reverse transcriptase inhibitors (NNRTIs) were
evaluated using the Monogram Biosciences PhenoSense GT
(PSGT) assay at screening, weeks 24 and 48, time of treatment
failure and early termination visit. These results were used to
calculate genotypic (GSS), phenotypic (PSS), and overall (OSS)
susceptibility scores for the OBT activity in each patient. OSS is
a composite score, which takes into account both genotypic and
in vitro phenotypic susceptibility of the virus to each component
of the OBT regimen [7]. For each drug in OBT, a score of “1”
was assigned if the virus from the patient was sensitive to the
drug and a score of “0” if the virus showed reduced susceptibility
to the drug. Primary and secondary end points were evaluated
within patient subgroups deﬁned by GSS, PSS, and OSS of 0, 1,
2, and 3 at baseline. A treatment beneﬁt for maraviroc for all
end points was observed for each OSS group. The MOTIVATE
studies showed that the clinical beneﬁt of maraviroc in patients
with CCR5-tropic virus, when used as add-on therapy to OBT
compared to OBT alone, is greater in patients in whom fewer of
the drugs comprising the OBT regimen are virologically active.
To explore the economic implications of this clinical ﬁnding, the
analysis was repeated according to OSS subgroup. Observed
virologic suppression rates for the two treatment arms for
patients with an OSS of 2 or less and individuals with an OSS of
3 or greater were substituted for the base-case values, holding all
other efﬁcacy inputs constant (Table 8).
The results of these analyses are shown in Figure 4 and
Table 9, which demonstrates that the results are relatively
insensitive to the majority of the variables tested, with the model
Table 7 Total discounted cost, quality-adjusted life years (QALYs), incremental cost-effectiveness ratios (ICERs) for the base-case analysis in 2008
Mexican pesos (US$)*
Strategy
Cost ($) QALY Life years ICER
Total (US$) Incr. (US$) Total Incr. Total Incr. Cost per QALY Cost per life year (US$)
MOTIVATE screening cohort
Treat with OBT alone 1,002,664 (93,709) 4.4209 5.4033
Test and treat with MVC
contingent on test result
1,230,879 (115,038) 228,215 (21,329) 4.9236 0.5027 5.9977 0.5945 453,978 (42,429) 383,904 (35,880)
MOTIVATE trial cohort
Treat with OBT alone 1,042,604 (97,442) 4.7282 8.1249
Test and treat with MVC 1,487,511 (139,023) 444,904 (41,581) 5.7306 1.0024 10.4639 2.3390 443,823 (41,480) 190,211 (17,777)
*Discount rate was 5% for costs and outcomes per annum.
MVC, maraviroc; OBT, optimized background therapy.
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being most sensitive to changes in the discount rate and to the
assumptions regarding the CD4+ increase in suppressed patients
after 48 weeks. In these particular sensitivity analyses, results
ranges from as low as $343,714 (US$32,124) when no discount-
ing was applied to costs and outcomes, to as high as $598,397
(US$55,926) when it was assumed that there was no increase in
CD4+ cell count in suppressed patients after week 48. The results
were most sensitive to the OSS subgroup analyses; when the
observed virologic suppression rates for the two treatment arms
for patients with an OSS of 2 or less and individuals with an OSS
of 3 or greater were substituted for the base-case values, the
respective ICERs were $407,329 (US$38,069) and $718,718
(US$67,171) per QALY gained.
Although probabilistic sensitivity analysis (PSA) is very
helpful in assessing the uncertainties in all model parameters
simultaneously, a PSA was not conducted because of the compu-
tational expense of the microsimulation approach when com-
bined with PSA. While methods have been proposed to overcome
this problem and were explored during model development, we
concluded that PSA was not feasible within ARAMIS. It was felt
by the authors that this trade off in favor of a microsimulation
approach was desirable to enable the modeling of switching
because of sequential treatment failure over several lines of
therapy and to allow memory of individual patient progression
to impact subsequent probabilities. These capabilities are gener-
ally not possible to incorporate using a cohort approach which is
more amenable to PSA. Instead, a wide range of deterministic
and multiway sensitivity analyses were conducted to explore the
impacts of uncertainty in the model.
Discussion
According to the National Center for the Prevention and Control
of HIV/AIDS, over 182,000 HIV-infected people live in Mexico
[2]. As in the rest of the Latin American countries, the HIV/AIDS
epidemiology in Mexico is concentrated in risk practice groups.
In the late 1990s, the Mexican Health System began scaling up
access to ART. Unfortunately, increased access to HIV therapies
Table 8 Efﬁcacy parameters from the MOTIVATE trials for OSS sub-
group analysis
MVC + OBT (CCR5+)* OBT alone†
24 weeks 48 weeks 24 weeks 48 weeks
Probability of treatment
success at 24 and
48 weeks‡§
OSS 2 56.80% 53.40% 13.90% 9.50%
OSS 3 70.60% 62.70% 58.20% 49.30%
Monthly probability of
success during and
after the ﬁrst six months‡§
OSS 2 0.910 0.990 0.719 0.939
OSS 3 0.944 0.980 0.914 0.973
*Number of MOTIVATE subjects receiving maraviroc plus OBT in OSS 2 was 296 and in
OSS 3 was 126 (data pooled over both trials).
†Number of MOTIVATE subjects receiving OBT in OSS 2 was 137 and in OSS 3 was 67
(data pooled over both trials).
‡Pooled 48-week data from trials A4001027 and A4001028 (MOTIVATE-1 and -2). Pﬁzer
Global Research and Development, data on ﬁle.
§Success is deﬁned as viral load dropping below detectable levels (<400 copies/mL).
MVC, maraviroc; OBT, optimized background therapy.
$444,849
$423,168
$437,775
$412,637
$418,550
$407,329
$484,813
$491,828
$504,556
$598,397
$718,718
$343,714
$434,087
$455,161
$440,675
$395,062
$515,620
$477,720
$472,512
$471,621
$467,533
$463,821
$459,342
$100,000 $250,000 $400,000 $550,000 $700,000 $850,000
Viral load set point
(<50; MOTIVATE baseline; >100,000)
Treatment failure time after treatment initiation (constant rate)*
(2; base; 10 years)
Late failure rates for OBT+MVC and OBT
(upper 95% CI; mean; lower 95% CI)
Lag time between failure and switch to OBT
(2; 4; 6 months)
Sensitivity/Specificity of tropism test
(100%/100%; 85%/94%)
All efficacy parameters for OBT+MVC and OBT
(lower 95% CI; mean; upper 95% CI)
Virologic suppression
95% CI OBT+MVC (60.8%; 56.1%; 51.4%)
Proportion CCR5 monotropic
(80%; 51%; 30%)
Time to treatment failure in suppressed patients
(5; 10; 100 years)
Cost per day of OBT
(50%; 100%; 150%)
Cost per day of maraviroc
($165; $181.5; $220)
Alternative utility values
(110%; 100%; 90%)
All efficacy parmeters for OBT+MVC
(upper 95% CI; mean; lower 95% CI)
Discount rate 
(0%; 5%)
CD4+ increase after 48 weeks when suppressed for all treatments
(base; zero)
OSS Subgroups
(≤2; all; ≥3)
Incremental cost  per QALY gained (2008 Mexican Pesos)
$452,567 $463,482
$448,867 $452,162
$452,904 $462,073
2008 US$
$38,069 / $67,171 
$42,429 / $55,926 
$32,124 / $42,429 
$39,118 / $48,190 
$38,565 / $47,156 
$40,914 / $45,966 
$39,549 / $45,311 
$40,570 / $44,648 
$42,539 / $44,161 
$41,186 / $44,078 
$41,576 / $43,696 
$42,429 / $43,349 
$42,297 / $43,317 
$42,328 / $43,185 
$36,922 / $42,930 
$41,951 / $42,259 
Figure 4 Tornado diagram of sensitivity and subgroup analyses on discounted ICER for test and treat with maraviroc strategy compared to treat with OBT strategy
for MOTIVATE screening cohort. Base-case ICER = $453,978/QALY (US$42,429) gained. CI, conﬁdence interval; MVC, maraviroc; OBT, optimized background
therapy;OSS, overall susceptibility score; *values for 2 years and 10 years shown; results for 4, 6, and 8 years were as follows: $424,455 ($39,670), $437,607 ($40,899),
and $447,498 ($41,823), respectively.
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resulted in prescription practices that were largely inconsistent
with published guidelines, with patients receiving anywhere from
4 to 13 changes in their treatment regimens [5]. Due to these low
levels of adherence to prescribing recommendations, it has been
speculated that the rate of development of multidrug resistant
HIV strains has increased in Mexico, though studies are required
to conﬁrm this hypothesis [5]. In order to prevent disease pro-
gression and death in these individuals, new treatments with
novel mechanisms of action are urgently needed.
As an emerging country, Mexico spends only approximately
6.6% of the gross domestic product on health services, resulting
in limited resources being available for drug funding. Since 2003,
all antiretroviral-indicated HIV patients were granted free access
to treatment [36], with funding being provided by the Mexican
government and health institutions. In this context, economic
assessments for new antiretroviral medications are important to
allow Mexican decision-makers to optimize use of limited health
care resources for an increasing HIV/AIDS population challenged
by the emergence of drug-resistant viral strains after exposure to
multiple treatment regimens.
The purpose of this study was to predict the long-term clinical
impact and cost-effectiveness of maraviroc in treatment-
experienced adults with HIV/AIDS in Mexico. The analysis was
conducted by adapting the previously published and validated
ARAMIS model to the perspective of health care payers in
Mexico to compare a strategy in which individuals are treated
with OBT, with or without the addition of maraviroc contingent
on viral tropism test results, versus a strategy of treating the
entire population with OBT alone (without testing for tropism
status) in treatment-experienced patients with HIV/AIDS.
The antiviral effect of maraviroc is the result of binding to the
human chemokine receptor CCR5, preventing CCR5-tropic
HIV-1 from entering cells. Because its mechanism of action
differs from that of all existing classes of ART, viruses that are
resistant to existing agents may remain susceptible to maraviroc.
In the MOTIVATE studies, patients treated with maraviroc plus
OBT experienced a signiﬁcant reduction in viral load and greater
increases in CD4+ cells at 48 weeks than those who received
OBT alone, in spite of the fact that patients had extensive pre-
existing resistance to multiple antiretroviral agents [8,9].
As with most clinical trials of antiretrovirals that are designed
with surrogate marker end points to meet regulatory require-
ments for accelerated approval, the 48-week follow-up period of
the MOTIVATE trials was not designed to demonstrate differ-
ences between treatments in clinical end points. However, eco-
nomic evaluations should employ a time horizon sufﬁciently
distant to capture all the clinical consequences and costs likely to
result from the studied interventions. In HIV/AIDS, the relation-
ships between immunologic and virologic markers, treatment,
and longer-term clinical outcomes have been well documented
through longitudinal cohort studies [15,18,37,38]. Making use
of this information, the ARAMIS model of HIV/AIDS disease
progression was used to project important long-term beneﬁts of
maraviroc treatment associated with the proven short-term viral
load reductions and CD4+ cell increases. ARAMIS has been
validated against observational trials and results of the previ-
ously published CEPAC model [10].
By adapting ARAMIS with Mexico-speciﬁc natural mortality
data and HIV-related resource use and costs, which differ mark-
edly from corresponding US data, the present study provides
results that are applicable to the Mexican setting. Our analysis
predicted increases in AIDS-free survival time of approximately
10 months (38% increase) and average life expectancy of 14
months (approximately 15.5% increase) for the contingent
maraviroc strategy relative to the OBT alone strategy. The pre-
dicted ICER under base-case assumptions of approximately
$454,000 (US$42,400) per QALY compares favorably to ICERs
reported for other ARTs in treatment-experienced patients [39].
Although no ofﬁcial declarations have been made on Mexican
payers’ valuations of a QALY, the ICER obtained falls below
$50,000 per QALY gained, which has been suggested as a thresh-
old applicable in the neighboring United States [40]. Alterna-
tively, using the criterion for cost-effectiveness recommended by
the World Health Organization’s Commission on Macroeconom-
ics and Health of less than three times the country’s gross domes-
tic product per capita (i.e., 3 ¥ US$10,751 [41] =US$32,253 per
QALY gained), the ICER falls slightly above this threshold. Nev-
ertheless, in the absence of an ofﬁcial Mexican threshold, the
reality is that additional issues, such as the complexity and sever-
ity of the disease state, for example, may be considered in the
Mexican decision-making process.
Consistent with the clinical trial ﬁndings, the beneﬁts associ-
atedwithmaraviroc treatmentwere augmented in the subgroup of
patients who had two or less active agents in their OBT regimen
(i.e., OSS score  2). Although the virological suppression rate
associated with maraviroc for the OSS  2 subgroup was similar
to that of the full trial population, the suppression rate associated
with OBT was substantially lower in the OSS  2 subgroup.
Consequently, greater increases in mean life expectancy and
quality-adjusted life expectancy of 0.77 years and 0.65 QALYs,
respectively, were predicted relative to treatment with OBT alone.
The resultant ICER associated with this subgroup deﬁned by OSS
score was considerably lower than for the base-case population at
$407,329 (US$38,069) per QALY gained for the contingent
maraviroc strategy versus OBT alone, indicating that maraviroc
may provide the most value when used in this scenario.
The choice of antiretrovirals continues to grow as new agents
are introduced. Because this analysis and the MOTIVATE trials
were completed, new agents introduced include darunavir,
tipranavir, etravirine, and raltegravir, all of which are indicated in
treatment-experienced patients. In this analysis, the modeled
population is prescribed OBT regimens similar to those used in
the MOTIVATE trials. Further, it relies on the results of the
TORO-1 and -2 trials [42,43] for efﬁcacy assumptions for
reoptimized background therapy. These assumptions may no
longer be as valid as they were at the time of analysis, because of
the introduction of new treatment options.
Our analysis has reported results for two different scenarios: a
contingent maraviroc strategy versus treatment with OBT alone
modeled on the MOTIVATE screening cohort, and a comparison
of maraviroc + OBT versus OBT alone based on the MOTIVATE
trial population (i.e., CCR5 tropic individuals only). Although our
discussion has focused primarily on the contingent strategy
involving the MOTIVATE screening cohort, the analysis based on
the MOTIVATE trial population is also of interest for Mexican
decision-makers. Economic evaluations are valuable tools in the
decision-making process, especially in developing countries where
resources are scarce and where cost containment policies are the
priority in government agendas. AIDS is a high prevalence disease
worldwide and Mexico is no exception. In this sense, results such
as the ones presented in this research could help to allocate more
efﬁciently the limited budget available to Mexicans Institutions.
Conclusions
Based on the substantial virologic, immunologic, and projected
clinical improvements associated with maraviroc, a treatment
strategy including this unique therapy is valuable and, from a
Mexican payer perspective, may be cost-effective in patients with
advanced HIV/AIDS and limited therapeutic options for active
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ART, whose prognosis is otherwise poor. Screening for tropism
status prior to maraviroc utilization will help to ensure it is used
appropriately and that health care dollars are invested in those
who are most likely to beneﬁt from its efﬁcacy.
Source of ﬁnancial support: This study was sponsored by Pﬁzer Inc.
Editorial support and the development of the model was provided by i3
Innovus and was funded by Pﬁzer Inc. The authors from i3 Innovus did
not receive individual payments from Pﬁzer for their involvement in the
model and article development.
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